echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Bicyclic peptide conjugate therapy for bladder cancer achieves 50% objective response rate

    Bicyclic peptide conjugate therapy for bladder cancer achieves 50% objective response rate

    • Last Update: 2022-05-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Bicycle Therapeutics today announced the latest clinical trial results of its investigational bicyclic peptide-based therapy BT8009 at the AACR Annual Meeting
    .
    BT8009 is the company's second-generation bicyclic peptide-conjugated toxin targeting Nectin-4

    .
    Trial results showed a confirmed overall response rate of 50% in a cohort of urothelial cancer patients treated with BT8009 at a weekly dose of 5.
    0 mg/m2

    .

    Bicyclic peptide technology incorporates chemical modifications into polypeptides to form a fixed three-dimensional molecular conformation
    .
    Bicyclic peptide molecules combine the properties of antibodies, small molecule drugs and peptides, and have similar affinity and specificity as antibodies; at the same time, they have smaller molecular weights and can penetrate quickly and deeply into tissues; their peptide properties provide A tunable pharmacokinetic half-life and renal clearance pathway avoids liver and gastrointestinal toxicity common in other drug forms

    .

    ▲Characteristic comparison of bicyclic peptides with small molecules and antibodies (Image source: Bicycle Therapeutics official website)

    In this clinical trial, 49% of patients with solid tumors who had received an average of 3 prior therapies and received different doses of BT8009 were patients with urothelial carcinoma
    .
    Results of the trial showed that of 8 patients with urothelial carcinoma treated with BT8009 at a weekly dose of 5.
    0 mg/m2, 4 patients achieved confirmed responses and one patient achieved a complete response

    .
    Two other patients had stable disease with a disease control rate of 75%

    .
    As of March 7 of this year, the median duration of response had not been reached, and the response was still maintained in 3 patients who received treatment for at least 24 weeks

    .

    ▲Trial data of BT8009 in the treatment of patients with urothelial carcinoma (5.
    0 mg/m2 per week, picture source: Bicycle Therapeutics official website)

    In terms of safety, no dose-limiting toxicities were found in the 2.
    5 mg/m2 or 5.
    0 mg/m2 dose groups

    .
    Skin and ocular toxicity, neuropathy and risk of hyperglycemia are low

    .
    Neutropenia occurred in 30% of patients treated with BT8009

    .

    "We believe the differentiated pharmacokinetic profile of bicyclic peptide-conjugated toxins has the potential to lead to better patient outcomes," said Bicycle CEO Dr.
    Kevin Lee, "We look forward to providing additional updates on BT8009 this year and An update to our extensive bicyclic peptide oncology pipeline

    .
    "

    References:

    [1] Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting.
    Retrieved April 9, 2022, from https://investors.
    bicycletherapeutics.
    com/news-releases/news-release-details/bicycle- therapeutics-present-interim-bt8009-phase-i-clinical

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.